Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
A secondary-ion mass spectrometer consists of (1) a primary ion gun generating the primary ion beam, (2) a primary ion column, accelerating and focusing the beam onto the sample (and in some devices an opportunity to separate the primary ion species by Wien filter or to pulse the beam), (3) high-vacuum sample chamber holding the sample and the secondary-ion extraction lens, (4) a mass analyzer separating the ions according to their mass-to-charge ratios, and (5) a detector.
=== Analogues === A notable analogue of SDA is 4T-MMDA-2 (2-methoxy-4T-MDA), which was described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved). Other analogues of SDA include SDMA, MDA, MDMA, 5-APB, 5-APDB, and 6-APBT, among others.
=== Impersonation attempts === Despite a seven-page document written by Twitter's content moderation team, on November 9, Twitter Blue launched with verification exclusively on iOS. Upon introducing paid verification, various individuals in sports Twitter were impersonated, such as sports writer Adam Schefter and basketball player LeBron James, with tweets announcing the supposed ousting of Las Vegas Raiders head coach Josh McDaniels or James' trade from the Los Angeles Lakers, respectively. As impersonation accounts began appearing for Nintendo and Tesla—the latter being owned by Musk—the official label returned. Other individuals and companies impersonated include former president Donald Trump, video game company Valve, and former New York City mayor Rudy Giuliani. One account impersonating the beverage corporation PepsiCo praised the superiority of Coca-Cola. Twitter paused signups for Twitter Blue on November 11; according to a Slack message obtained by Platformer reporter Zoë Schiffer, the company paused subscriptions to deal with impersonation attempts. Musk believed that impersonation would be resolved if Apple handed over the credit card information of Twitter Blue subscribers; then head of trust and safety Yoel Roth explained that Apple would not oblige to such a request. The Washington Post published a report on November 11 detailing how reporter Geoffrey Fowler was, with permission from United States senator Ed Markey, impersonating a U.S.
=== Threats to critical seabed infrastructure === During the Cold War, Russia relied on the ability of its nuclear submarines to pass through the GIUK gap in order to ensure maximum military capability. The introduction of long-range precision strike weapons, however, have reduced the significance of the GIUK gap in relation to intercontinental attacks and made it possible for Russia to target North American sites from safer waters, such as the Norwegian Sea. Still, the GIUK gap remains the obvious access point for Russian military operations in the wider North Atlantic Ocean since most of Russia's highest quality naval capabilities are deployed in the Northern fleet, making the GIUK gap a significant transit route. For NATO allies, the GIUK gap is vital in terms of barrier defense for sea lines of communication protection. SLOCs are vulnerable in the North Atlantic both in the gap and beyond, and the US and NATO rely on Denmark to assist in protecting this critical infrastructure, including the vast number of seabed data cables. The Russian fleet has in recent years strategically upgraded its capabilities for covert subsea operations related to the targeting of seabed infrastructure and reports of Russian "mapping" of critical seabed infrastructure in the North Sea and the seabed around Denmark are increasing. NATO intelligence and security officials confirm these reports, warning that Russia has both the intent and necessary capabilities to target critical seabed installations if they so choose.
=== In genetic disorders === Many genetic disorders involve hereditary defects in receptor genes. Often, it is hard to determine whether the receptor is nonfunctional or the hormone is produced at decreased level; this gives rise to the "pseudo-hypo-" group of endocrine disorders, where there appears to be a decreased hormonal level while in fact it is the receptor that is not responding sufficiently to the hormone.
Sources: en.wikipedia.org
A more commonly used parameter is the half-life T1/2. Given a sample of a particular radionuclide, the half-life is the time taken for half the radionuclide's atoms to decay. For the case of one-decay nuclear reactions:
Small integral membrane protein 20 (SMIM20) is a protein that in humans is encoded by the SMIM20 gene. SMIM20 acts as a prohormone to the peptide hormone phoenixin (PNX) which was discovered for the first time in 2013 in rodent sensory ganglia. Two alternate cleavage sites within SMIM20 results in two different phoenixin products, Phoenixin-14 (PNX-14) and Phoenixin-20 (PNX-20). In the study of the evolution of nervous systems, SMIM20 together with NUCB2 have been found to have deep homology across all lineages that preceded creatures with central nervous systems, bilaterians, cnidarians, ctenophores, and sponges as well as in choanoflagellates.
644 1787 L'intégration de quelques équations aux différences Partielles (Legendre transform) In Memoires présentés par divers Savants à la l'Académie des Sciences de l'Institut de France 1806 Nouvelle formula pour réduire en distances vraies les distances apparentes de la Lune au Soleil ou à une étoile (30–54) 1807 Analyse des triangles tracés sur la surface d'un sphéroide (130–161) Tome 10 Recherches sur diverses sortes d'intégrales défines (416–509) 1819 Méthode des moindres carrés pour trouver le milieu le plus probable entre les résultats de différentes observations (149–154), Mémoire sur l'attraction des ellipsoïdes homogènes (155–183) 1823 Recherches sur quelques objets d'Analyse indéterminée et particulièrement sur le théorème de Fermat (1–60) 1828 Mémoire sur la détermination des fonctions Y et Z que satisfont à l'équation 4(X^n-1) = (X-1)(Y^2+-nZ^2), n étant un nombre premier 4i-+1 (81–100) 1833 Réflexions sur différentes manières de démontrer la théorie des parallèles ou le théorème sur la somme des trois angles du triangle, avec 1 planche (367–412)
In humans, the homolog gene, TDH, is a non-functional pseudogene. The loss of an acceptor splice site consistently leads to a non-functional truncated protein. The primary pathway for threonine degradation in humans instead starts with threonine ammonia-lyase (aka threonine dehydratase) and produces propionyl-CoA instead of glycine.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.